India-Based Dhiti Omics is Now Live on SOPHiA DDMtm

The diagnostics company has implemented the SOPHiA DDMtm Platform to enhance its solid tumor testing

BOSTON and ROLLE, Switzerland, July 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA DDMtm Platform. The company will use SOPHiA GENETICS' technology to enhance its solid tumor testing capabilities.

Dhiti Omics specializes in molecular diagnostic and genetic testing. By implementing SOPHiA DDMtm for the Agilent SureSelect Cancer CGP application, Dhiti Omics will improve its ability to provide researchers actionable information on mutations and biomarkers across hundreds of genes.

"Our team at Dhiti Omics is passionate about furthering the use of precision medicine and ensuring people in India and throughout the world have access to testing for better health outcomes," said Sudha N. Rao, Ph.D., Founder and Director of Dhiti Omics Technologies. "Combining high-quality reagents, and powerful analytics into one unique workflow will help us maximize insights from comprehensive genomic profiling data. This will ensure we're delivering the fastest and most accurate diagnostics to our customer base."

SOPHiA DDMtm for SureSelect CGP application combines Agilent's best-in-class genomic profiling assay kit with the SOPHiA DDMtm Platform. Launched in 2023, SureSelect Cancer CGP application offers comprehensive genomic profiling. With the SOPHiA DDMtm AI Platform, Dhiti Omics will have an integrated solution for rapid and accurate insights on the basis of the latest guidelines reflecting relevant biomarkers.

"Our Platform and applications are designed to enable companies like Dhiti Omics to more easily advance precision medicine," said Ricardo Mendonca Filho, Ph.D., Managing Director, LAPAC, SOPHiA GENETICS. "By using SOPHiA DDMtm, Dhiti Omics can ensure speed and accuracy of solid tumor testing to best support the Indian population."

The combined efforts of Agilent and SOPHiA GENETICS make it possible for companies like Dhiti Omics to facilitate novel approaches to cancer research and diagnostics.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.

About SOPHiA GENETICS 
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDMtm Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.  For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

SOURCE SOPHiA GENETICS